nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MERTK—multiple sclerosis	0.343	0.597	CbGaD
Crizotinib—TYK2—multiple sclerosis	0.231	0.403	CbGaD
Crizotinib—ABCB1—Methylprednisolone—multiple sclerosis	0.00442	0.115	CbGbCtD
Crizotinib—CYP3A4—Fingolimod—multiple sclerosis	0.00411	0.107	CbGbCtD
Crizotinib—ABCB1—Mitoxantrone—multiple sclerosis	0.00322	0.0841	CbGbCtD
Crizotinib—ABCB1—Betamethasone—multiple sclerosis	0.00287	0.075	CbGbCtD
Crizotinib—ABCB1—Prednisolone—multiple sclerosis	0.00283	0.074	CbGbCtD
Crizotinib—ABCB1—Prednisone—multiple sclerosis	0.00268	0.0698	CbGbCtD
Crizotinib—CYP3A4—Methylprednisolone—multiple sclerosis	0.00265	0.0691	CbGbCtD
Crizotinib—CYP3A5—Dexamethasone—multiple sclerosis	0.00257	0.067	CbGbCtD
Crizotinib—CYP3A4—Triamcinolone—multiple sclerosis	0.00201	0.0523	CbGbCtD
Crizotinib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00193	0.0504	CbGbCtD
Crizotinib—CYP3A4—Betamethasone—multiple sclerosis	0.00172	0.0449	CbGbCtD
Crizotinib—CYP3A4—Prednisolone—multiple sclerosis	0.0017	0.0443	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—multiple sclerosis	0.00167	0.0436	CbGbCtD
Crizotinib—CYP3A4—Prednisone—multiple sclerosis	0.0016	0.0418	CbGbCtD
Crizotinib—ABCB1—Methotrexate—multiple sclerosis	0.00134	0.035	CbGbCtD
Crizotinib—CYP3A4—Dexamethasone—multiple sclerosis	0.001	0.0261	CbGbCtD
Crizotinib—DCLK1—cerebellum—multiple sclerosis	0.000314	0.003	CbGeAlD
Crizotinib—TYRO3—nervous system—multiple sclerosis	0.000311	0.00297	CbGeAlD
Crizotinib—EPHA5—nervous system—multiple sclerosis	0.000311	0.00297	CbGeAlD
Crizotinib—FER—nervous system—multiple sclerosis	0.000311	0.00297	CbGeAlD
Crizotinib—ALK—nervous system—multiple sclerosis	0.000311	0.00297	CbGeAlD
Crizotinib—MAPK7—brain—multiple sclerosis	0.00031	0.00297	CbGeAlD
Crizotinib—STK4—cerebellum—multiple sclerosis	0.00031	0.00296	CbGeAlD
Crizotinib—LYN—nervous system—multiple sclerosis	0.000309	0.00296	CbGeAlD
Crizotinib—EPHA4—medulla oblongata—multiple sclerosis	0.000307	0.00294	CbGeAlD
Crizotinib—EPHA8—brain—multiple sclerosis	0.000307	0.00294	CbGeAlD
Crizotinib—FES—brain—multiple sclerosis	0.000307	0.00294	CbGeAlD
Crizotinib—BMPR1B—nervous system—multiple sclerosis	0.000305	0.00291	CbGeAlD
Crizotinib—MAP3K19—nervous system—multiple sclerosis	0.000305	0.00291	CbGeAlD
Crizotinib—BMP2K—midbrain—multiple sclerosis	0.000303	0.0029	CbGeAlD
Crizotinib—TYRO3—central nervous system—multiple sclerosis	0.000299	0.00286	CbGeAlD
Crizotinib—FER—central nervous system—multiple sclerosis	0.000299	0.00286	CbGeAlD
Crizotinib—ALK—central nervous system—multiple sclerosis	0.000299	0.00286	CbGeAlD
Crizotinib—EPHA5—central nervous system—multiple sclerosis	0.000299	0.00286	CbGeAlD
Crizotinib—IGF1R—nervous system—multiple sclerosis	0.000299	0.00286	CbGeAlD
Crizotinib—TNK2—nervous system—multiple sclerosis	0.000299	0.00286	CbGeAlD
Crizotinib—LYN—central nervous system—multiple sclerosis	0.000298	0.00285	CbGeAlD
Crizotinib—BMP2K—spinal cord—multiple sclerosis	0.000296	0.00283	CbGeAlD
Crizotinib—AURKA—Floxuridine—Cladribine—multiple sclerosis	0.000296	0.1	CbGdCrCtD
Crizotinib—TBK1—medulla oblongata—multiple sclerosis	0.000295	0.00282	CbGeAlD
Crizotinib—BMPR1B—central nervous system—multiple sclerosis	0.000293	0.0028	CbGeAlD
Crizotinib—MAP3K19—central nervous system—multiple sclerosis	0.000293	0.0028	CbGeAlD
Crizotinib—TYK2—medulla oblongata—multiple sclerosis	0.000293	0.0028	CbGeAlD
Crizotinib—FER—cerebellum—multiple sclerosis	0.000293	0.0028	CbGeAlD
Crizotinib—TYRO3—cerebellum—multiple sclerosis	0.000293	0.0028	CbGeAlD
Crizotinib—EPHA5—cerebellum—multiple sclerosis	0.000293	0.0028	CbGeAlD
Crizotinib—TIE1—nervous system—multiple sclerosis	0.000291	0.00278	CbGeAlD
Crizotinib—MET—brain—multiple sclerosis	0.000291	0.00278	CbGeAlD
Crizotinib—RIPK2—midbrain—multiple sclerosis	0.000291	0.00278	CbGeAlD
Crizotinib—TNK1—cerebellum—multiple sclerosis	0.00029	0.00277	CbGeAlD
Crizotinib—TNK2—central nervous system—multiple sclerosis	0.000288	0.00275	CbGeAlD
Crizotinib—IGF1R—central nervous system—multiple sclerosis	0.000288	0.00275	CbGeAlD
Crizotinib—BMPR1B—cerebellum—multiple sclerosis	0.000287	0.00274	CbGeAlD
Crizotinib—RPS6KB1—medulla oblongata—multiple sclerosis	0.000284	0.00271	CbGeAlD
Crizotinib—RIPK2—spinal cord—multiple sclerosis	0.000284	0.00271	CbGeAlD
Crizotinib—AURKA—nervous system—multiple sclerosis	0.000283	0.00271	CbGeAlD
Crizotinib—TNK2—cerebellum—multiple sclerosis	0.000281	0.00269	CbGeAlD
Crizotinib—IGF1R—cerebellum—multiple sclerosis	0.000281	0.00269	CbGeAlD
Crizotinib—AXL—medulla oblongata—multiple sclerosis	0.000281	0.00269	CbGeAlD
Crizotinib—CDK7—brain—multiple sclerosis	0.000281	0.00269	CbGeAlD
Crizotinib—TESK1—nervous system—multiple sclerosis	0.000281	0.00269	CbGeAlD
Crizotinib—TIE1—central nervous system—multiple sclerosis	0.00028	0.00267	CbGeAlD
Crizotinib—TAOK2—brain—multiple sclerosis	0.000279	0.00267	CbGeAlD
Crizotinib—MAP4K2—cerebellum—multiple sclerosis	0.000277	0.00265	CbGeAlD
Crizotinib—TIE1—cerebellum—multiple sclerosis	0.000274	0.00261	CbGeAlD
Crizotinib—STK3—cerebellum—multiple sclerosis	0.000274	0.00261	CbGeAlD
Crizotinib—MERTK—nervous system—multiple sclerosis	0.000273	0.00261	CbGeAlD
Crizotinib—AURKA—central nervous system—multiple sclerosis	0.000273	0.00261	CbGeAlD
Crizotinib—SLK—medulla oblongata—multiple sclerosis	0.000271	0.00259	CbGeAlD
Crizotinib—TESK1—central nervous system—multiple sclerosis	0.000271	0.00259	CbGeAlD
Crizotinib—TBK1—midbrain—multiple sclerosis	0.00027	0.00258	CbGeAlD
Crizotinib—PTK2—midbrain—multiple sclerosis	0.00027	0.00258	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—multiple sclerosis	0.000269	0.00257	CbGeAlD
Crizotinib—EPHA3—brain—multiple sclerosis	0.000269	0.00257	CbGeAlD
Crizotinib—ACVR1B—brain—multiple sclerosis	0.000269	0.00257	CbGeAlD
Crizotinib—TYK2—midbrain—multiple sclerosis	0.000268	0.00256	CbGeAlD
Crizotinib—LIMK2—nervous system—multiple sclerosis	0.000267	0.00255	CbGeAlD
Crizotinib—JAK2—medulla oblongata—multiple sclerosis	0.000267	0.00255	CbGeAlD
Crizotinib—IRAK1—midbrain—multiple sclerosis	0.000265	0.00253	CbGeAlD
Crizotinib—ACVR1—nervous system—multiple sclerosis	0.000264	0.00253	CbGeAlD
Crizotinib—MAP3K12—nervous system—multiple sclerosis	0.000264	0.00253	CbGeAlD
Crizotinib—TESK1—cerebellum—multiple sclerosis	0.000264	0.00253	CbGeAlD
Crizotinib—TBK1—spinal cord—multiple sclerosis	0.000263	0.00252	CbGeAlD
Crizotinib—PTK2—spinal cord—multiple sclerosis	0.000263	0.00252	CbGeAlD
Crizotinib—MERTK—central nervous system—multiple sclerosis	0.000263	0.00251	CbGeAlD
Crizotinib—TYK2—spinal cord—multiple sclerosis	0.000261	0.0025	CbGeAlD
Crizotinib—RPS6KB1—midbrain—multiple sclerosis	0.00026	0.00248	CbGeAlD
Crizotinib—STK35—nervous system—multiple sclerosis	0.000259	0.00248	CbGeAlD
Crizotinib—LIMK2—central nervous system—multiple sclerosis	0.000257	0.00246	CbGeAlD
Crizotinib—MERTK—cerebellum—multiple sclerosis	0.000257	0.00246	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—multiple sclerosis	0.000257	0.00246	CbGeAlD
Crizotinib—TEK—medulla oblongata—multiple sclerosis	0.000257	0.00246	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—multiple sclerosis	0.000257	0.00246	CbGeAlD
Crizotinib—AXL—midbrain—multiple sclerosis	0.000257	0.00246	CbGeAlD
Crizotinib—EPHA6—brain—multiple sclerosis	0.000256	0.00245	CbGeAlD
Crizotinib—JAK3—brain—multiple sclerosis	0.000256	0.00245	CbGeAlD
Crizotinib—DCLK1—brain—multiple sclerosis	0.000255	0.00243	CbGeAlD
Crizotinib—ACVR1—central nervous system—multiple sclerosis	0.000255	0.00243	CbGeAlD
Crizotinib—MAP3K12—central nervous system—multiple sclerosis	0.000255	0.00243	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—multiple sclerosis	0.000253	0.00242	CbGeAlD
Crizotinib—PLK4—brain—multiple sclerosis	0.000253	0.00242	CbGeAlD
Crizotinib—STK4—brain—multiple sclerosis	0.000252	0.0024	CbGeAlD
Crizotinib—LIMK2—cerebellum—multiple sclerosis	0.000252	0.0024	CbGeAlD
Crizotinib—AXL—spinal cord—multiple sclerosis	0.000251	0.0024	CbGeAlD
Crizotinib—NUAK2—cerebellum—multiple sclerosis	0.000251	0.0024	CbGeAlD
Crizotinib—STK35—central nervous system—multiple sclerosis	0.000249	0.00238	CbGeAlD
Crizotinib—BMP2K—nervous system—multiple sclerosis	0.000249	0.00238	CbGeAlD
Crizotinib—ACVR1—cerebellum—multiple sclerosis	0.000249	0.00238	CbGeAlD
Crizotinib—FLT3—cerebellum—multiple sclerosis	0.000249	0.00238	CbGeAlD
Crizotinib—MAP3K12—cerebellum—multiple sclerosis	0.000249	0.00238	CbGeAlD
Crizotinib—Infection—Cladribine—multiple sclerosis	0.000249	0.00249	CcSEcCtD
Crizotinib—SLK—midbrain—multiple sclerosis	0.000247	0.00236	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—multiple sclerosis	0.000246	0.00235	CbGeAlD
Crizotinib—EPHB4—midbrain—multiple sclerosis	0.000246	0.00235	CbGeAlD
Crizotinib—Nervous system disorder—Cladribine—multiple sclerosis	0.000245	0.00246	CcSEcCtD
Crizotinib—STK35—cerebellum—multiple sclerosis	0.000244	0.00233	CbGeAlD
Crizotinib—Skin disorder—Cladribine—multiple sclerosis	0.000243	0.00243	CcSEcCtD
Crizotinib—Muscular weakness—Prednisolone—multiple sclerosis	0.000242	0.00242	CcSEcCtD
Crizotinib—Visual disturbance—Dexamethasone—multiple sclerosis	0.000242	0.00242	CcSEcCtD
Crizotinib—Visual disturbance—Betamethasone—multiple sclerosis	0.000242	0.00242	CcSEcCtD
Crizotinib—SLK—spinal cord—multiple sclerosis	0.000241	0.00231	CbGeAlD
Crizotinib—PTK2B—nervous system—multiple sclerosis	0.000241	0.0023	CbGeAlD
Crizotinib—BMP2K—central nervous system—multiple sclerosis	0.00024	0.00229	CbGeAlD
Crizotinib—EPHB4—spinal cord—multiple sclerosis	0.00024	0.00229	CbGeAlD
Crizotinib—Sepsis—Prednisone—multiple sclerosis	0.000239	0.00239	CcSEcCtD
Crizotinib—JAK2—spinal cord—multiple sclerosis	0.000238	0.00227	CbGeAlD
Crizotinib—TYRO3—brain—multiple sclerosis	0.000238	0.00227	CbGeAlD
Crizotinib—FER—brain—multiple sclerosis	0.000238	0.00227	CbGeAlD
Crizotinib—EPHA5—brain—multiple sclerosis	0.000238	0.00227	CbGeAlD
Crizotinib—ALK—brain—multiple sclerosis	0.000238	0.00227	CbGeAlD
Crizotinib—ABL2—cerebellum—multiple sclerosis	0.000238	0.00227	CbGeAlD
Crizotinib—YES1—medulla oblongata—multiple sclerosis	0.000237	0.00227	CbGeAlD
Crizotinib—LYN—brain—multiple sclerosis	0.000237	0.00226	CbGeAlD
Crizotinib—Bradycardia—Mitoxantrone—multiple sclerosis	0.000236	0.00236	CcSEcCtD
Crizotinib—TNK1—brain—multiple sclerosis	0.000235	0.00225	CbGeAlD
Crizotinib—MAP4K5—midbrain—multiple sclerosis	0.000235	0.00225	CbGeAlD
Crizotinib—MAP3K3—midbrain—multiple sclerosis	0.000235	0.00225	CbGeAlD
Crizotinib—TEK—midbrain—multiple sclerosis	0.000235	0.00225	CbGeAlD
Crizotinib—BMP2K—cerebellum—multiple sclerosis	0.000235	0.00224	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—multiple sclerosis	0.000234	0.00224	CbGeAlD
Crizotinib—Respiratory failure—Methotrexate—multiple sclerosis	0.000234	0.00234	CcSEcCtD
Crizotinib—MAP4K1—brain—multiple sclerosis	0.000233	0.00223	CbGeAlD
Crizotinib—BMPR1B—brain—multiple sclerosis	0.000233	0.00223	CbGeAlD
Crizotinib—MAP3K19—brain—multiple sclerosis	0.000233	0.00223	CbGeAlD
Crizotinib—ABL1—brainstem—multiple sclerosis	0.000232	0.00222	CbGeAlD
Crizotinib—PTK2B—central nervous system—multiple sclerosis	0.000232	0.00222	CbGeAlD
Crizotinib—EPHA4—nervous system—multiple sclerosis	0.000231	0.00221	CbGeAlD
Crizotinib—Anaemia—Azathioprine—multiple sclerosis	0.000231	0.00231	CcSEcCtD
Crizotinib—Pulmonary embolism—Methotrexate—multiple sclerosis	0.00023	0.0023	CcSEcCtD
Crizotinib—MAP4K5—spinal cord—multiple sclerosis	0.000229	0.00219	CbGeAlD
Crizotinib—MAP3K3—spinal cord—multiple sclerosis	0.000229	0.00219	CbGeAlD
Crizotinib—TEK—spinal cord—multiple sclerosis	0.000229	0.00219	CbGeAlD
Crizotinib—TNK2—brain—multiple sclerosis	0.000228	0.00218	CbGeAlD
Crizotinib—IGF1R—brain—multiple sclerosis	0.000228	0.00218	CbGeAlD
Crizotinib—PTK2B—cerebellum—multiple sclerosis	0.000227	0.00217	CbGeAlD
Crizotinib—MAP3K2—nervous system—multiple sclerosis	0.000226	0.00216	CbGeAlD
Crizotinib—MAP4K2—brain—multiple sclerosis	0.000225	0.00215	CbGeAlD
Crizotinib—RIPK2—cerebellum—multiple sclerosis	0.000225	0.00215	CbGeAlD
Crizotinib—Paraesthesia—Cladribine—multiple sclerosis	0.000225	0.00225	CcSEcCtD
Crizotinib—EPHB6—midbrain—multiple sclerosis	0.000225	0.00215	CbGeAlD
Crizotinib—ABL1—retina—multiple sclerosis	0.000224	0.00214	CbGeAlD
Crizotinib—Leukopenia—Azathioprine—multiple sclerosis	0.000223	0.00223	CcSEcCtD
Crizotinib—Dyspnoea—Cladribine—multiple sclerosis	0.000223	0.00223	CcSEcCtD
Crizotinib—Muscular weakness—Triamcinolone—multiple sclerosis	0.000223	0.00223	CcSEcCtD
Crizotinib—EPHA4—central nervous system—multiple sclerosis	0.000222	0.00212	CbGeAlD
Crizotinib—Muscular weakness—Methylprednisolone—multiple sclerosis	0.000222	0.00222	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000222	0.00222	CcSEcCtD
Crizotinib—TIE1—brain—multiple sclerosis	0.000222	0.00212	CbGeAlD
Crizotinib—STK3—brain—multiple sclerosis	0.000222	0.00212	CbGeAlD
Crizotinib—TBK1—nervous system—multiple sclerosis	0.000222	0.00212	CbGeAlD
Crizotinib—PTK2—nervous system—multiple sclerosis	0.000222	0.00212	CbGeAlD
Crizotinib—TYK2—nervous system—multiple sclerosis	0.00022	0.00211	CbGeAlD
Crizotinib—EPHB6—spinal cord—multiple sclerosis	0.000219	0.00209	CbGeAlD
Crizotinib—MAP3K2—central nervous system—multiple sclerosis	0.000218	0.00208	CbGeAlD
Crizotinib—Decreased appetite—Cladribine—multiple sclerosis	0.000218	0.00218	CcSEcCtD
Crizotinib—EPHA4—cerebellum—multiple sclerosis	0.000217	0.00208	CbGeAlD
Crizotinib—YES1—midbrain—multiple sclerosis	0.000217	0.00207	CbGeAlD
Crizotinib—AURKA—brain—multiple sclerosis	0.000217	0.00207	CbGeAlD
Crizotinib—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000216	0.00216	CcSEcCtD
Crizotinib—Fatigue—Cladribine—multiple sclerosis	0.000216	0.00216	CcSEcCtD
Crizotinib—TESK1—brain—multiple sclerosis	0.000215	0.00205	CbGeAlD
Crizotinib—TAOK3—midbrain—multiple sclerosis	0.000214	0.00205	CbGeAlD
Crizotinib—Constipation—Cladribine—multiple sclerosis	0.000214	0.00214	CcSEcCtD
Crizotinib—TBK1—central nervous system—multiple sclerosis	0.000214	0.00204	CbGeAlD
Crizotinib—PTK2—central nervous system—multiple sclerosis	0.000214	0.00204	CbGeAlD
Crizotinib—RPS6KB1—nervous system—multiple sclerosis	0.000213	0.00204	CbGeAlD
Crizotinib—MAP3K2—cerebellum—multiple sclerosis	0.000213	0.00204	CbGeAlD
Crizotinib—TYK2—central nervous system—multiple sclerosis	0.000212	0.00203	CbGeAlD
Crizotinib—FGR—nervous system—multiple sclerosis	0.000212	0.00203	CbGeAlD
Crizotinib—YES1—spinal cord—multiple sclerosis	0.000212	0.00202	CbGeAlD
Crizotinib—AXL—nervous system—multiple sclerosis	0.000211	0.00202	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000211	0.00211	CcSEcCtD
Crizotinib—TAOK3—spinal cord—multiple sclerosis	0.000209	0.002	CbGeAlD
Crizotinib—MERTK—brain—multiple sclerosis	0.000209	0.002	CbGeAlD
Crizotinib—PTK2—cerebellum—multiple sclerosis	0.000209	0.00199	CbGeAlD
Crizotinib—TBK1—cerebellum—multiple sclerosis	0.000209	0.00199	CbGeAlD
Crizotinib—Hypokalaemia—Dexamethasone—multiple sclerosis	0.000209	0.00209	CcSEcCtD
Crizotinib—Hypokalaemia—Betamethasone—multiple sclerosis	0.000209	0.00209	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisolone—multiple sclerosis	0.000207	0.00208	CcSEcCtD
Crizotinib—TYK2—cerebellum—multiple sclerosis	0.000207	0.00198	CbGeAlD
Crizotinib—AURKA—Clofarabine—Cladribine—multiple sclerosis	0.000207	0.07	CbGdCrCtD
Crizotinib—Arrhythmia—Mitoxantrone—multiple sclerosis	0.000207	0.00207	CcSEcCtD
Crizotinib—RPS6KB1—central nervous system—multiple sclerosis	0.000205	0.00196	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—multiple sclerosis	0.000205	0.00196	CbGeAlD
Crizotinib—IRAK1—cerebellum—multiple sclerosis	0.000205	0.00196	CbGeAlD
Crizotinib—LIMK2—brain—multiple sclerosis	0.000204	0.00195	CbGeAlD
Crizotinib—FGR—central nervous system—multiple sclerosis	0.000204	0.00195	CbGeAlD
Crizotinib—SRC—spinal cord—multiple sclerosis	0.000204	0.00195	CbGeAlD
Crizotinib—NUAK2—brain—multiple sclerosis	0.000204	0.00195	CbGeAlD
Crizotinib—AXL—central nervous system—multiple sclerosis	0.000203	0.00194	CbGeAlD
Crizotinib—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000203	0.00203	CcSEcCtD
Crizotinib—Infection—Azathioprine—multiple sclerosis	0.000202	0.00202	CcSEcCtD
Crizotinib—MAP3K12—brain—multiple sclerosis	0.000202	0.00193	CbGeAlD
Crizotinib—ACVR1—brain—multiple sclerosis	0.000202	0.00193	CbGeAlD
Crizotinib—Muscular weakness—Dexamethasone—multiple sclerosis	0.000202	0.00202	CcSEcCtD
Crizotinib—Muscular weakness—Betamethasone—multiple sclerosis	0.000202	0.00202	CcSEcCtD
Crizotinib—RPS6KB1—cerebellum—multiple sclerosis	0.000201	0.00192	CbGeAlD
Crizotinib—JAK2—nervous system—multiple sclerosis	0.0002	0.00192	CbGeAlD
Crizotinib—Sepsis—Methotrexate—multiple sclerosis	0.000199	0.00199	CcSEcCtD
Crizotinib—AXL—cerebellum—multiple sclerosis	0.000199	0.0019	CbGeAlD
Crizotinib—STK35—brain—multiple sclerosis	0.000198	0.00189	CbGeAlD
Crizotinib—EPHA2—nervous system—multiple sclerosis	0.000198	0.00189	CbGeAlD
Crizotinib—Body temperature increased—Cladribine—multiple sclerosis	0.000198	0.00198	CcSEcCtD
Crizotinib—Skin disorder—Azathioprine—multiple sclerosis	0.000198	0.00198	CcSEcCtD
Crizotinib—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000197	0.00198	CcSEcCtD
Crizotinib—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000194	0.00194	CcSEcCtD
Crizotinib—Infestation—Methylprednisolone—multiple sclerosis	0.000194	0.00194	CcSEcCtD
Crizotinib—Bradycardia—Prednisolone—multiple sclerosis	0.000193	0.00194	CcSEcCtD
Crizotinib—MAP4K5—nervous system—multiple sclerosis	0.000193	0.00185	CbGeAlD
Crizotinib—MAP3K3—nervous system—multiple sclerosis	0.000193	0.00185	CbGeAlD
Crizotinib—TEK—nervous system—multiple sclerosis	0.000193	0.00185	CbGeAlD
Crizotinib—ABL2—brain—multiple sclerosis	0.000193	0.00184	CbGeAlD
Crizotinib—JAK2—central nervous system—multiple sclerosis	0.000193	0.00184	CbGeAlD
Crizotinib—Face oedema—Prednisone—multiple sclerosis	0.000193	0.00193	CcSEcCtD
Crizotinib—SLK—cerebellum—multiple sclerosis	0.000191	0.00183	CbGeAlD
Crizotinib—Neuropathy peripheral—Triamcinolone—multiple sclerosis	0.000191	0.00191	CcSEcCtD
Crizotinib—EPHA2—central nervous system—multiple sclerosis	0.000191	0.00182	CbGeAlD
Crizotinib—BMP2K—brain—multiple sclerosis	0.000191	0.00182	CbGeAlD
Crizotinib—Neuropathy peripheral—Methylprednisolone—multiple sclerosis	0.00019	0.0019	CcSEcCtD
Crizotinib—Vision blurred—Mitoxantrone—multiple sclerosis	0.00019	0.0019	CcSEcCtD
Crizotinib—EPHB4—cerebellum—multiple sclerosis	0.00019	0.00182	CbGeAlD
Crizotinib—JAK2—cerebellum—multiple sclerosis	0.000189	0.0018	CbGeAlD
Crizotinib—CSF1R—midbrain—multiple sclerosis	0.000187	0.00179	CbGeAlD
Crizotinib—Anaemia—Mitoxantrone—multiple sclerosis	0.000186	0.00186	CcSEcCtD
Crizotinib—MAP3K3—central nervous system—multiple sclerosis	0.000186	0.00178	CbGeAlD
Crizotinib—TEK—central nervous system—multiple sclerosis	0.000186	0.00178	CbGeAlD
Crizotinib—MAP4K5—central nervous system—multiple sclerosis	0.000186	0.00178	CbGeAlD
Crizotinib—Hepatic failure—Methotrexate—multiple sclerosis	0.000186	0.00186	CcSEcCtD
Crizotinib—EPHB6—nervous system—multiple sclerosis	0.000185	0.00176	CbGeAlD
Crizotinib—PTK2B—brain—multiple sclerosis	0.000184	0.00176	CbGeAlD
Crizotinib—Visual impairment—Prednisolone—multiple sclerosis	0.000183	0.00183	CcSEcCtD
Crizotinib—CSF1R—spinal cord—multiple sclerosis	0.000183	0.00175	CbGeAlD
Crizotinib—RIPK2—brain—multiple sclerosis	0.000183	0.00175	CbGeAlD
Crizotinib—TEK—cerebellum—multiple sclerosis	0.000182	0.00174	CbGeAlD
Crizotinib—MAP4K5—cerebellum—multiple sclerosis	0.000182	0.00174	CbGeAlD
Crizotinib—MAP3K3—cerebellum—multiple sclerosis	0.000182	0.00174	CbGeAlD
Crizotinib—Hypokalaemia—Prednisone—multiple sclerosis	0.000182	0.00182	CcSEcCtD
Crizotinib—Leukopenia—Mitoxantrone—multiple sclerosis	0.00018	0.00181	CcSEcCtD
Crizotinib—Asthenia—Cladribine—multiple sclerosis	0.00018	0.0018	CcSEcCtD
Crizotinib—Weight decreased—Betamethasone—multiple sclerosis	0.000179	0.00179	CcSEcCtD
Crizotinib—Weight decreased—Dexamethasone—multiple sclerosis	0.000179	0.00179	CcSEcCtD
Crizotinib—YES1—nervous system—multiple sclerosis	0.000178	0.00171	CbGeAlD
Crizotinib—Bradycardia—Triamcinolone—multiple sclerosis	0.000178	0.00178	CcSEcCtD
Crizotinib—EPHB6—central nervous system—multiple sclerosis	0.000178	0.0017	CbGeAlD
Crizotinib—Bradycardia—Methylprednisolone—multiple sclerosis	0.000177	0.00178	CcSEcCtD
Crizotinib—STK10—nervous system—multiple sclerosis	0.000177	0.00169	CbGeAlD
Crizotinib—EPHA4—brain—multiple sclerosis	0.000177	0.00169	CbGeAlD
Crizotinib—TAOK3—nervous system—multiple sclerosis	0.000176	0.00168	CbGeAlD
Crizotinib—Muscular weakness—Prednisone—multiple sclerosis	0.000176	0.00176	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000176	0.00176	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—multiple sclerosis	0.000176	0.00176	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000176	0.00176	CcSEcCtD
Crizotinib—EPHB6—cerebellum—multiple sclerosis	0.000174	0.00166	CbGeAlD
Crizotinib—MAP3K2—brain—multiple sclerosis	0.000173	0.00165	CbGeAlD
Crizotinib—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.000173	0.00173	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.000173	0.00173	CcSEcCtD
Crizotinib—YES1—central nervous system—multiple sclerosis	0.000172	0.00164	CbGeAlD
Crizotinib—SRC—nervous system—multiple sclerosis	0.000172	0.00164	CbGeAlD
Crizotinib—Diarrhoea—Cladribine—multiple sclerosis	0.000171	0.00171	CcSEcCtD
Crizotinib—STK10—central nervous system—multiple sclerosis	0.00017	0.00163	CbGeAlD
Crizotinib—Arrhythmia—Prednisolone—multiple sclerosis	0.00017	0.0017	CcSEcCtD
Crizotinib—TAOK3—central nervous system—multiple sclerosis	0.00017	0.00162	CbGeAlD
Crizotinib—TBK1—brain—multiple sclerosis	0.00017	0.00162	CbGeAlD
Crizotinib—PTK2—brain—multiple sclerosis	0.00017	0.00162	CbGeAlD
Crizotinib—TYK2—brain—multiple sclerosis	0.000168	0.00161	CbGeAlD
Crizotinib—Visual impairment—Methylprednisolone—multiple sclerosis	0.000168	0.00168	CcSEcCtD
Crizotinib—YES1—cerebellum—multiple sclerosis	0.000168	0.0016	CbGeAlD
Crizotinib—STK10—cerebellum—multiple sclerosis	0.000166	0.00159	CbGeAlD
Crizotinib—IRAK1—brain—multiple sclerosis	0.000166	0.00159	CbGeAlD
Crizotinib—TAOK3—cerebellum—multiple sclerosis	0.000166	0.00158	CbGeAlD
Crizotinib—Dizziness—Cladribine—multiple sclerosis	0.000166	0.00166	CcSEcCtD
Crizotinib—SRC—central nervous system—multiple sclerosis	0.000165	0.00158	CbGeAlD
Crizotinib—Oedema—Mitoxantrone—multiple sclerosis	0.000165	0.00165	CcSEcCtD
Crizotinib—Infection—Mitoxantrone—multiple sclerosis	0.000163	0.00164	CcSEcCtD
Crizotinib—RPS6KB1—brain—multiple sclerosis	0.000163	0.00156	CbGeAlD
Crizotinib—Eye disorder—Methylprednisolone—multiple sclerosis	0.000163	0.00163	CcSEcCtD
Crizotinib—ABL1—medulla oblongata—multiple sclerosis	0.000162	0.00155	CbGeAlD
Crizotinib—FGR—brain—multiple sclerosis	0.000162	0.00155	CbGeAlD
Crizotinib—Shock—Mitoxantrone—multiple sclerosis	0.000162	0.00162	CcSEcCtD
Crizotinib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000162	0.00162	CcSEcCtD
Crizotinib—SRC—cerebellum—multiple sclerosis	0.000162	0.00154	CbGeAlD
Crizotinib—AXL—brain—multiple sclerosis	0.000161	0.00154	CbGeAlD
Crizotinib—Bradycardia—Dexamethasone—multiple sclerosis	0.000161	0.00161	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—multiple sclerosis	0.000161	0.00161	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—multiple sclerosis	0.000161	0.00161	CcSEcCtD
Crizotinib—Body temperature increased—Azathioprine—multiple sclerosis	0.000161	0.00161	CcSEcCtD
Crizotinib—Skin disorder—Mitoxantrone—multiple sclerosis	0.00016	0.0016	CcSEcCtD
Crizotinib—Vomiting—Cladribine—multiple sclerosis	0.000159	0.00159	CcSEcCtD
Crizotinib—Rash—Cladribine—multiple sclerosis	0.000158	0.00158	CcSEcCtD
Crizotinib—Dermatitis—Cladribine—multiple sclerosis	0.000158	0.00158	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Methylprednisolone—multiple sclerosis	0.000157	0.0531	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000157	0.0531	CbGdCrCtD
Crizotinib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000157	0.00157	CcSEcCtD
Crizotinib—Arrhythmia—Triamcinolone—multiple sclerosis	0.000156	0.00156	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—multiple sclerosis	0.000156	0.00156	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—multiple sclerosis	0.000156	0.00156	CcSEcCtD
Crizotinib—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000156	0.00156	CcSEcCtD
Crizotinib—SLK—brain—multiple sclerosis	0.000155	0.00149	CbGeAlD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—multiple sclerosis	0.000155	0.0523	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—multiple sclerosis	0.000155	0.0523	CbGdCrCtD
Crizotinib—EPHB4—brain—multiple sclerosis	0.000154	0.00147	CbGeAlD
Crizotinib—CSF1R—nervous system—multiple sclerosis	0.000154	0.00147	CbGeAlD
Crizotinib—JAK2—brain—multiple sclerosis	0.000153	0.00146	CbGeAlD
Crizotinib—Visual impairment—Betamethasone—multiple sclerosis	0.000153	0.00153	CcSEcCtD
Crizotinib—Visual impairment—Dexamethasone—multiple sclerosis	0.000153	0.00153	CcSEcCtD
Crizotinib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000152	0.00152	CcSEcCtD
Crizotinib—EPHA2—brain—multiple sclerosis	0.000151	0.00145	CbGeAlD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—multiple sclerosis	0.000151	0.0511	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—multiple sclerosis	0.000151	0.0511	CbGdCrCtD
Crizotinib—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000151	0.00151	CcSEcCtD
Crizotinib—Dysgeusia—Triamcinolone—multiple sclerosis	0.000149	0.00149	CcSEcCtD
Crizotinib—Nausea—Cladribine—multiple sclerosis	0.000149	0.00149	CcSEcCtD
Crizotinib—CSF1R—central nervous system—multiple sclerosis	0.000148	0.00142	CbGeAlD
Crizotinib—Syncope—Prednisolone—multiple sclerosis	0.000148	0.00148	CcSEcCtD
Crizotinib—ABL1—midbrain—multiple sclerosis	0.000148	0.00142	CbGeAlD
Crizotinib—Eye disorder—Betamethasone—multiple sclerosis	0.000148	0.00148	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—multiple sclerosis	0.000148	0.00148	CcSEcCtD
Crizotinib—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000148	0.00148	CcSEcCtD
Crizotinib—MAP4K5—brain—multiple sclerosis	0.000148	0.00141	CbGeAlD
Crizotinib—TEK—brain—multiple sclerosis	0.000148	0.00141	CbGeAlD
Crizotinib—MAP3K3—brain—multiple sclerosis	0.000148	0.00141	CbGeAlD
Crizotinib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000147	0.00147	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—multiple sclerosis	0.000145	0.00145	CcSEcCtD
Crizotinib—CSF1R—cerebellum—multiple sclerosis	0.000145	0.00139	CbGeAlD
Crizotinib—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000145	0.00145	CcSEcCtD
Crizotinib—ABL1—spinal cord—multiple sclerosis	0.000145	0.00138	CbGeAlD
Crizotinib—ACVR1—Dexamethasone—Prednisone—multiple sclerosis	0.000143	0.0485	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—multiple sclerosis	0.000143	0.0485	CbGdCrCtD
Crizotinib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000143	0.00143	CcSEcCtD
Crizotinib—Fatigue—Mitoxantrone—multiple sclerosis	0.000142	0.00142	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—multiple sclerosis	0.000142	0.00142	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—multiple sclerosis	0.000142	0.00142	CcSEcCtD
Crizotinib—EPHB6—brain—multiple sclerosis	0.000141	0.00135	CbGeAlD
Crizotinib—Constipation—Mitoxantrone—multiple sclerosis	0.000141	0.00141	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—multiple sclerosis	0.000141	0.00141	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—multiple sclerosis	0.00014	0.0473	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—multiple sclerosis	0.00014	0.0473	CbGdCrCtD
Crizotinib—Diarrhoea—Azathioprine—multiple sclerosis	0.000139	0.00139	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—multiple sclerosis	0.000136	0.00136	CcSEcCtD
Crizotinib—YES1—brain—multiple sclerosis	0.000136	0.0013	CbGeAlD
Crizotinib—Syncope—Methylprednisolone—multiple sclerosis	0.000136	0.00136	CcSEcCtD
Crizotinib—STK10—brain—multiple sclerosis	0.000135	0.00129	CbGeAlD
Crizotinib—Oedema—Prednisolone—multiple sclerosis	0.000135	0.00135	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—multiple sclerosis	0.000135	0.00135	CcSEcCtD
Crizotinib—TAOK3—brain—multiple sclerosis	0.000135	0.00129	CbGeAlD
Crizotinib—Dizziness—Azathioprine—multiple sclerosis	0.000135	0.00135	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000134	0.00134	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000134	0.00134	CcSEcCtD
Crizotinib—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000133	0.00133	CcSEcCtD
Crizotinib—Shock—Prednisolone—multiple sclerosis	0.000133	0.00133	CcSEcCtD
Crizotinib—SRC—brain—multiple sclerosis	0.000131	0.00125	CbGeAlD
Crizotinib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00013	0.0013	CcSEcCtD
Crizotinib—Vomiting—Azathioprine—multiple sclerosis	0.000129	0.00129	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—multiple sclerosis	0.000129	0.00129	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—multiple sclerosis	0.000129	0.00129	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—multiple sclerosis	0.000129	0.00129	CcSEcCtD
Crizotinib—Infestation—Methotrexate—multiple sclerosis	0.000129	0.00129	CcSEcCtD
Crizotinib—Rash—Azathioprine—multiple sclerosis	0.000128	0.00128	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000128	0.00128	CcSEcCtD
Crizotinib—Dermatitis—Azathioprine—multiple sclerosis	0.000128	0.00128	CcSEcCtD
Crizotinib—Oedema—Triamcinolone—multiple sclerosis	0.000124	0.00124	CcSEcCtD
Crizotinib—Syncope—Betamethasone—multiple sclerosis	0.000124	0.00124	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—multiple sclerosis	0.000124	0.00124	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—multiple sclerosis	0.000123	0.00123	CcSEcCtD
Crizotinib—Infection—Triamcinolone—multiple sclerosis	0.000123	0.00123	CcSEcCtD
Crizotinib—Infection—Methylprednisolone—multiple sclerosis	0.000123	0.00123	CcSEcCtD
Crizotinib—Shock—Triamcinolone—multiple sclerosis	0.000122	0.00122	CcSEcCtD
Crizotinib—Shock—Methylprednisolone—multiple sclerosis	0.000122	0.00122	CcSEcCtD
Crizotinib—ABL1—nervous system—multiple sclerosis	0.000122	0.00116	CbGeAlD
Crizotinib—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000122	0.00122	CcSEcCtD
Crizotinib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000121	0.00122	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000121	0.00121	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—multiple sclerosis	0.000121	0.00121	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—multiple sclerosis	0.000121	0.00121	CcSEcCtD
Crizotinib—Nausea—Azathioprine—multiple sclerosis	0.000121	0.00121	CcSEcCtD
Crizotinib—Skin disorder—Methylprednisolone—multiple sclerosis	0.00012	0.0012	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—multiple sclerosis	0.00012	0.0012	CcSEcCtD
Crizotinib—Asthenia—Mitoxantrone—multiple sclerosis	0.000118	0.00118	CcSEcCtD
Crizotinib—CSF1R—brain—multiple sclerosis	0.000118	0.00113	CbGeAlD
Crizotinib—ABL1—central nervous system—multiple sclerosis	0.000117	0.00112	CbGeAlD
Crizotinib—ABL1—cerebellum—multiple sclerosis	0.000115	0.0011	CbGeAlD
Crizotinib—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000114	0.00114	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—multiple sclerosis	0.000113	0.00113	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—multiple sclerosis	0.000113	0.00113	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—multiple sclerosis	0.000113	0.00113	CcSEcCtD
Crizotinib—Oedema—Betamethasone—multiple sclerosis	0.000113	0.00113	CcSEcCtD
Crizotinib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000113	0.00113	CcSEcCtD
Crizotinib—Infection—Dexamethasone—multiple sclerosis	0.000112	0.00112	CcSEcCtD
Crizotinib—Infection—Betamethasone—multiple sclerosis	0.000112	0.00112	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—multiple sclerosis	0.000111	0.00112	CcSEcCtD
Crizotinib—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000111	0.00111	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—multiple sclerosis	0.000111	0.00111	CcSEcCtD
Crizotinib—Anaemia—Prednisone—multiple sclerosis	0.000111	0.00111	CcSEcCtD
Crizotinib—Shock—Betamethasone—multiple sclerosis	0.000111	0.00111	CcSEcCtD
Crizotinib—Shock—Dexamethasone—multiple sclerosis	0.000111	0.00111	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000111	0.00111	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00011	0.00111	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—multiple sclerosis	0.00011	0.00111	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—multiple sclerosis	0.000109	0.00109	CcSEcCtD
Crizotinib—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000109	0.00109	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—multiple sclerosis	0.000108	0.00108	CcSEcCtD
Crizotinib—Syncope—Prednisone—multiple sclerosis	0.000108	0.00108	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000107	0.00107	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—multiple sclerosis	0.000107	0.00107	CcSEcCtD
Crizotinib—Fatigue—Methylprednisolone—multiple sclerosis	0.000107	0.00107	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—multiple sclerosis	0.000106	0.00106	CcSEcCtD
Crizotinib—Vomiting—Mitoxantrone—multiple sclerosis	0.000105	0.00105	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000104	0.00104	CcSEcCtD
Crizotinib—Rash—Mitoxantrone—multiple sclerosis	0.000104	0.00104	CcSEcCtD
Crizotinib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000104	0.00104	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000102	0.00102	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Methylprednisolone—multiple sclerosis	0.000101	0.0342	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000101	0.0342	CbGdCrCtD
Crizotinib—Paraesthesia—Betamethasone—multiple sclerosis	0.000101	0.00101	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—multiple sclerosis	0.000101	0.00101	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—multiple sclerosis	0.0001	0.001	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—multiple sclerosis	9.97e-05	0.0337	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—multiple sclerosis	9.97e-05	0.0337	CbGdCrCtD
Crizotinib—Dyspepsia—Dexamethasone—multiple sclerosis	9.92e-05	0.000992	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—multiple sclerosis	9.92e-05	0.000992	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—multiple sclerosis	9.84e-05	0.000984	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—multiple sclerosis	9.81e-05	0.000982	CcSEcCtD
Crizotinib—Oedema—Prednisone—multiple sclerosis	9.81e-05	0.000981	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—multiple sclerosis	9.79e-05	0.00098	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—multiple sclerosis	9.79e-05	0.00098	CcSEcCtD
Crizotinib—Nausea—Mitoxantrone—multiple sclerosis	9.77e-05	0.000978	CcSEcCtD
Crizotinib—Infection—Prednisone—multiple sclerosis	9.75e-05	0.000975	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—multiple sclerosis	9.74e-05	0.0329	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—multiple sclerosis	9.74e-05	0.0329	CbGdCrCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	9.72e-05	0.000973	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	9.72e-05	0.000973	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—multiple sclerosis	9.71e-05	0.000972	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—multiple sclerosis	9.71e-05	0.000972	CcSEcCtD
Crizotinib—Shock—Prednisone—multiple sclerosis	9.65e-05	0.000965	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—multiple sclerosis	9.62e-05	0.000962	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—multiple sclerosis	9.53e-05	0.000953	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—multiple sclerosis	9.47e-05	0.000947	CcSEcCtD
Crizotinib—ABL1—brain—multiple sclerosis	9.31e-05	0.00089	CbGeAlD
Crizotinib—Anaemia—Methotrexate—multiple sclerosis	9.28e-05	0.000929	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—multiple sclerosis	9.24e-05	0.0312	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—multiple sclerosis	9.24e-05	0.0312	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—multiple sclerosis	9.02e-05	0.0305	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—multiple sclerosis	9.02e-05	0.0305	CbGdCrCtD
Crizotinib—Leukopenia—Methotrexate—multiple sclerosis	8.99e-05	0.0009	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—multiple sclerosis	8.93e-05	0.000893	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—multiple sclerosis	8.91e-05	0.000891	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—multiple sclerosis	8.9e-05	0.000891	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—multiple sclerosis	8.9e-05	0.000891	CcSEcCtD
Crizotinib—Asthenia—Methylprednisolone—multiple sclerosis	8.89e-05	0.000889	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—multiple sclerosis	8.81e-05	0.000881	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—multiple sclerosis	8.63e-05	0.000864	CcSEcCtD
Crizotinib—Decreased appetite—Prednisone—multiple sclerosis	8.53e-05	0.000853	CcSEcCtD
Crizotinib—Rash—Prednisolone—multiple sclerosis	8.51e-05	0.000851	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—multiple sclerosis	8.5e-05	0.000851	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	8.49e-05	0.00085	CcSEcCtD
Crizotinib—Diarrhoea—Methylprednisolone—multiple sclerosis	8.47e-05	0.000848	CcSEcCtD
Crizotinib—Fatigue—Prednisone—multiple sclerosis	8.46e-05	0.000846	CcSEcCtD
Crizotinib—Constipation—Prednisone—multiple sclerosis	8.39e-05	0.000839	CcSEcCtD
Crizotinib—Dizziness—Triamcinolone—multiple sclerosis	8.21e-05	0.000821	CcSEcCtD
Crizotinib—Dizziness—Methylprednisolone—multiple sclerosis	8.19e-05	0.000819	CcSEcCtD
Crizotinib—Infection—Methotrexate—multiple sclerosis	8.14e-05	0.000815	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—multiple sclerosis	8.08e-05	0.000808	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—multiple sclerosis	8.08e-05	0.000808	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—multiple sclerosis	8.04e-05	0.000804	CcSEcCtD
Crizotinib—Nausea—Prednisolone—multiple sclerosis	8.02e-05	0.000802	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—multiple sclerosis	7.96e-05	0.000797	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—multiple sclerosis	7.89e-05	0.00079	CcSEcCtD
Crizotinib—Vomiting—Methylprednisolone—multiple sclerosis	7.88e-05	0.000788	CcSEcCtD
Crizotinib—Rash—Triamcinolone—multiple sclerosis	7.83e-05	0.000783	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—multiple sclerosis	7.82e-05	0.000782	CcSEcCtD
Crizotinib—Rash—Methylprednisolone—multiple sclerosis	7.81e-05	0.000781	CcSEcCtD
Crizotinib—Dermatitis—Methylprednisolone—multiple sclerosis	7.8e-05	0.000781	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—multiple sclerosis	7.75e-05	0.000776	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—multiple sclerosis	7.71e-05	0.000771	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—multiple sclerosis	7.71e-05	0.000771	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—multiple sclerosis	7.45e-05	0.000745	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—multiple sclerosis	7.45e-05	0.000745	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—multiple sclerosis	7.37e-05	0.000738	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—multiple sclerosis	7.36e-05	0.000736	CcSEcCtD
Crizotinib—Nausea—Methylprednisolone—multiple sclerosis	7.36e-05	0.000736	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—multiple sclerosis	7.31e-05	0.000731	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—multiple sclerosis	7.22e-05	0.000722	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—multiple sclerosis	7.16e-05	0.000716	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—multiple sclerosis	7.16e-05	0.000716	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—multiple sclerosis	7.13e-05	0.000713	CcSEcCtD
Crizotinib—Rash—Dexamethasone—multiple sclerosis	7.1e-05	0.00071	CcSEcCtD
Crizotinib—Rash—Betamethasone—multiple sclerosis	7.1e-05	0.00071	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—multiple sclerosis	7.1e-05	0.00071	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—multiple sclerosis	7.1e-05	0.00071	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	7.08e-05	0.000708	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—multiple sclerosis	7.07e-05	0.000707	CcSEcCtD
Crizotinib—Asthenia—Prednisone—multiple sclerosis	7.04e-05	0.000704	CcSEcCtD
Crizotinib—ABCB1—retina—multiple sclerosis	6.97e-05	0.000667	CbGeAlD
Crizotinib—Diarrhoea—Prednisone—multiple sclerosis	6.71e-05	0.000671	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—multiple sclerosis	6.69e-05	0.000669	CcSEcCtD
Crizotinib—Nausea—Betamethasone—multiple sclerosis	6.69e-05	0.000669	CcSEcCtD
Crizotinib—Dizziness—Prednisone—multiple sclerosis	6.49e-05	0.000649	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—multiple sclerosis	6.48e-05	0.000648	CcSEcCtD
Crizotinib—Vomiting—Prednisone—multiple sclerosis	6.24e-05	0.000624	CcSEcCtD
Crizotinib—Rash—Prednisone—multiple sclerosis	6.18e-05	0.000619	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—multiple sclerosis	6.18e-05	0.000618	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—multiple sclerosis	5.88e-05	0.000588	CcSEcCtD
Crizotinib—Nausea—Prednisone—multiple sclerosis	5.83e-05	0.000583	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—multiple sclerosis	5.61e-05	0.000561	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—multiple sclerosis	5.42e-05	0.000542	CcSEcCtD
Crizotinib—CYP3A4—nervous system—multiple sclerosis	5.35e-05	0.000511	CbGeAlD
Crizotinib—Vomiting—Methotrexate—multiple sclerosis	5.21e-05	0.000521	CcSEcCtD
Crizotinib—Rash—Methotrexate—multiple sclerosis	5.17e-05	0.000517	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—multiple sclerosis	5.16e-05	0.000517	CcSEcCtD
Crizotinib—CYP3A4—central nervous system—multiple sclerosis	5.15e-05	0.000492	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—multiple sclerosis	5.04e-05	0.000482	CbGeAlD
Crizotinib—Nausea—Methotrexate—multiple sclerosis	4.87e-05	0.000487	CcSEcCtD
Crizotinib—ABCB1—midbrain—multiple sclerosis	4.61e-05	0.00044	CbGeAlD
Crizotinib—ABCB1—spinal cord—multiple sclerosis	4.5e-05	0.00043	CbGeAlD
Crizotinib—ABCB1—nervous system—multiple sclerosis	3.79e-05	0.000362	CbGeAlD
Crizotinib—ABCB1—central nervous system—multiple sclerosis	3.65e-05	0.000348	CbGeAlD
Crizotinib—ABCB1—cerebellum—multiple sclerosis	3.56e-05	0.000341	CbGeAlD
Crizotinib—ABCB1—brain—multiple sclerosis	2.9e-05	0.000277	CbGeAlD
Crizotinib—RIPK2—Signaling Pathways—IL2—multiple sclerosis	1.91e-06	1.06e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNG—multiple sclerosis	1.91e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—TLR4—multiple sclerosis	1.91e-06	1.06e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCR5—multiple sclerosis	1.91e-06	1.06e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DRB1—multiple sclerosis	1.91e-06	1.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—multiple sclerosis	1.9e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—multiple sclerosis	1.88e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2RA—multiple sclerosis	1.88e-06	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TGFB1—multiple sclerosis	1.88e-06	1.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL2—multiple sclerosis	1.85e-06	1.03e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—multiple sclerosis	1.85e-06	1.03e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—multiple sclerosis	1.84e-06	1.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—multiple sclerosis	1.84e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TGFB1—multiple sclerosis	1.84e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MAPK1—multiple sclerosis	1.84e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD80—multiple sclerosis	1.84e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—MAPK1—multiple sclerosis	1.83e-06	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SPP1—multiple sclerosis	1.83e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ICAM1—multiple sclerosis	1.83e-06	1.02e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—STAT3—multiple sclerosis	1.82e-06	1.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—multiple sclerosis	1.82e-06	1.01e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MMP9—multiple sclerosis	1.81e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—MAPK1—multiple sclerosis	1.8e-06	1e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—STAT3—multiple sclerosis	1.8e-06	1e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—multiple sclerosis	1.8e-06	1e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TYK2—multiple sclerosis	1.8e-06	1e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL2—multiple sclerosis	1.8e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APOE—multiple sclerosis	1.8e-06	1e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—multiple sclerosis	1.79e-06	9.98e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCR5—multiple sclerosis	1.78e-06	9.92e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL10—multiple sclerosis	1.78e-06	9.92e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MMP9—multiple sclerosis	1.78e-06	9.9e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TYK2—multiple sclerosis	1.78e-06	9.88e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—MAPK1—multiple sclerosis	1.77e-06	9.86e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—STAT3—multiple sclerosis	1.77e-06	9.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TYK2—multiple sclerosis	1.77e-06	9.84e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD86—multiple sclerosis	1.76e-06	9.8e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—MAPK1—multiple sclerosis	1.76e-06	9.8e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD80—multiple sclerosis	1.76e-06	9.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2RA—multiple sclerosis	1.76e-06	9.78e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—multiple sclerosis	1.75e-06	9.74e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—MAPK1—multiple sclerosis	1.75e-06	9.72e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—multiple sclerosis	1.75e-06	9.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—multiple sclerosis	1.75e-06	9.71e-06	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—multiple sclerosis	1.74e-06	9.69e-06	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—multiple sclerosis	1.74e-06	9.65e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL5—multiple sclerosis	1.73e-06	9.65e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APOE—multiple sclerosis	1.73e-06	9.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—multiple sclerosis	1.73e-06	9.64e-06	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—multiple sclerosis	1.72e-06	9.56e-06	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—multiple sclerosis	1.71e-06	9.52e-06	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—multiple sclerosis	1.71e-06	9.51e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—multiple sclerosis	1.71e-06	9.51e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MMP9—multiple sclerosis	1.7e-06	9.48e-06	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—multiple sclerosis	1.7e-06	9.48e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—multiple sclerosis	1.7e-06	9.48e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—multiple sclerosis	1.7e-06	9.47e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—multiple sclerosis	1.7e-06	9.43e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TYK2—multiple sclerosis	1.68e-06	9.37e-06	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—multiple sclerosis	1.68e-06	9.34e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—TYK2—multiple sclerosis	1.68e-06	9.34e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—multiple sclerosis	1.68e-06	9.32e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—multiple sclerosis	1.67e-06	9.29e-06	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—multiple sclerosis	1.67e-06	9.29e-06	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—multiple sclerosis	1.66e-06	9.26e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—MAPK1—multiple sclerosis	1.66e-06	9.22e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—multiple sclerosis	1.65e-06	9.19e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MAPK1—multiple sclerosis	1.64e-06	9.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—STAT3—multiple sclerosis	1.63e-06	9.09e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD80—multiple sclerosis	1.63e-06	9.04e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—MAPK1—multiple sclerosis	1.62e-06	9.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—multiple sclerosis	1.62e-06	9.03e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—MAPK1—multiple sclerosis	1.61e-06	8.95e-06	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—multiple sclerosis	1.61e-06	8.95e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SPP1—multiple sclerosis	1.61e-06	8.94e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—STAT3—multiple sclerosis	1.61e-06	8.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—multiple sclerosis	1.6e-06	8.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—multiple sclerosis	1.6e-06	8.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—multiple sclerosis	1.59e-06	8.87e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.59e-06	8.83e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—STAT3—multiple sclerosis	1.58e-06	8.81e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—multiple sclerosis	1.57e-06	8.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CD80—multiple sclerosis	1.57e-06	8.72e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—multiple sclerosis	1.56e-06	8.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD86—multiple sclerosis	1.56e-06	8.68e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TYK2—multiple sclerosis	1.55e-06	8.62e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2RA—multiple sclerosis	1.54e-06	8.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL5—multiple sclerosis	1.54e-06	8.54e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—multiple sclerosis	1.52e-06	8.45e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—multiple sclerosis	1.52e-06	8.44e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—STAT3—multiple sclerosis	1.52e-06	8.43e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—multiple sclerosis	1.52e-06	8.43e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—multiple sclerosis	1.5e-06	8.33e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—multiple sclerosis	1.49e-06	8.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—multiple sclerosis	1.49e-06	8.29e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.49e-06	8.28e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—multiple sclerosis	1.49e-06	8.28e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—MAPK1—multiple sclerosis	1.49e-06	8.26e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—TYK2—multiple sclerosis	1.49e-06	8.26e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—BCHE—multiple sclerosis	1.48e-06	8.23e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—multiple sclerosis	1.48e-06	8.22e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—multiple sclerosis	1.47e-06	8.18e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—STAT3—multiple sclerosis	1.47e-06	8.17e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—multiple sclerosis	1.47e-06	8.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CD80—multiple sclerosis	1.47e-06	8.16e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MAPK1—multiple sclerosis	1.46e-06	8.12e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—multiple sclerosis	1.46e-06	8.11e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MAPK1—multiple sclerosis	1.44e-06	8.01e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—STAT3—multiple sclerosis	1.43e-06	7.97e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—STAT3—multiple sclerosis	1.43e-06	7.94e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPP1—multiple sclerosis	1.42e-06	7.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—multiple sclerosis	1.42e-06	7.91e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—multiple sclerosis	1.42e-06	7.89e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—multiple sclerosis	1.41e-06	7.86e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—multiple sclerosis	1.41e-06	7.84e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—multiple sclerosis	1.41e-06	7.83e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—multiple sclerosis	1.4e-06	7.81e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—multiple sclerosis	1.4e-06	7.8e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—multiple sclerosis	1.4e-06	7.79e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—multiple sclerosis	1.4e-06	7.79e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—multiple sclerosis	1.4e-06	7.78e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—multiple sclerosis	1.4e-06	7.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—multiple sclerosis	1.39e-06	7.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—multiple sclerosis	1.39e-06	7.74e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—multiple sclerosis	1.38e-06	7.69e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MAPK1—multiple sclerosis	1.38e-06	7.66e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TYK2—multiple sclerosis	1.37e-06	7.63e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—multiple sclerosis	1.37e-06	7.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—multiple sclerosis	1.36e-06	7.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2RA—multiple sclerosis	1.36e-06	7.58e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—multiple sclerosis	1.36e-06	7.58e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—multiple sclerosis	1.36e-06	7.58e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—multiple sclerosis	1.36e-06	7.57e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—multiple sclerosis	1.35e-06	7.53e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—multiple sclerosis	1.34e-06	7.47e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—multiple sclerosis	1.34e-06	7.47e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—STAT3—multiple sclerosis	1.34e-06	7.46e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MAPK1—multiple sclerosis	1.34e-06	7.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—MAPK1—multiple sclerosis	1.34e-06	7.43e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—multiple sclerosis	1.33e-06	7.38e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TYK2—multiple sclerosis	1.32e-06	7.36e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK1—multiple sclerosis	1.3e-06	7.25e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK1—multiple sclerosis	1.3e-06	7.22e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—multiple sclerosis	1.29e-06	7.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD80—multiple sclerosis	1.29e-06	7.15e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—multiple sclerosis	1.27e-06	7.09e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STAT3—multiple sclerosis	1.26e-06	7.01e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—multiple sclerosis	1.26e-06	7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—multiple sclerosis	1.26e-06	7e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—multiple sclerosis	1.25e-06	6.94e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STAT3—multiple sclerosis	1.24e-06	6.91e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—multiple sclerosis	1.24e-06	6.9e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—multiple sclerosis	1.24e-06	6.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TYK2—multiple sclerosis	1.24e-06	6.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—STAT3—multiple sclerosis	1.24e-06	6.89e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—multiple sclerosis	1.24e-06	6.88e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—multiple sclerosis	1.24e-06	6.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—multiple sclerosis	1.22e-06	6.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK1—multiple sclerosis	1.22e-06	6.78e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—multiple sclerosis	1.2e-06	6.65e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—multiple sclerosis	1.18e-06	6.56e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—multiple sclerosis	1.18e-06	6.56e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—multiple sclerosis	1.18e-06	6.54e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—multiple sclerosis	1.17e-06	6.52e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—multiple sclerosis	1.17e-06	6.5e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—multiple sclerosis	1.16e-06	6.43e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—multiple sclerosis	1.15e-06	6.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—multiple sclerosis	1.15e-06	6.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—multiple sclerosis	1.15e-06	6.39e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK1—multiple sclerosis	1.15e-06	6.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—multiple sclerosis	1.14e-06	6.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—multiple sclerosis	1.14e-06	6.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD80—multiple sclerosis	1.14e-06	6.33e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK1—multiple sclerosis	1.13e-06	6.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MAPK1—multiple sclerosis	1.13e-06	6.26e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—multiple sclerosis	1.12e-06	6.24e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—multiple sclerosis	1.11e-06	6.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—multiple sclerosis	1.1e-06	6.13e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—multiple sclerosis	1.1e-06	6.09e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—multiple sclerosis	1.09e-06	6.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TYK2—multiple sclerosis	1.09e-06	6.04e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—multiple sclerosis	1.09e-06	6.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—multiple sclerosis	1.08e-06	6.01e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK1—multiple sclerosis	1.07e-06	5.96e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK1—multiple sclerosis	1.07e-06	5.94e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—multiple sclerosis	1.06e-06	5.92e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—multiple sclerosis	1.06e-06	5.9e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—multiple sclerosis	1.06e-06	5.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—multiple sclerosis	1.06e-06	5.88e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—multiple sclerosis	1.04e-06	5.8e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK1—multiple sclerosis	1.04e-06	5.79e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—multiple sclerosis	1.04e-06	5.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—multiple sclerosis	1.03e-06	5.73e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—multiple sclerosis	1.03e-06	5.71e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—multiple sclerosis	1.03e-06	5.71e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—multiple sclerosis	1.01e-06	5.64e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—multiple sclerosis	1.01e-06	5.61e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—multiple sclerosis	1.01e-06	5.59e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—multiple sclerosis	1e-06	5.57e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—multiple sclerosis	9.97e-07	5.54e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK1—multiple sclerosis	9.87e-07	5.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—multiple sclerosis	9.76e-07	5.43e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TYK2—multiple sclerosis	9.61e-07	5.34e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—multiple sclerosis	9.61e-07	5.34e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK1—multiple sclerosis	9.46e-07	5.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—multiple sclerosis	9.37e-07	5.21e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—multiple sclerosis	9.27e-07	5.16e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—multiple sclerosis	9.24e-07	5.14e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—multiple sclerosis	9.12e-07	5.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—multiple sclerosis	9.03e-07	5.02e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—multiple sclerosis	8.93e-07	4.96e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—multiple sclerosis	8.91e-07	4.95e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—multiple sclerosis	8.91e-07	4.95e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—multiple sclerosis	8.81e-07	4.9e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK1—multiple sclerosis	8.73e-07	4.86e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—multiple sclerosis	8.69e-07	4.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—multiple sclerosis	8.68e-07	4.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—multiple sclerosis	8.65e-07	4.81e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—multiple sclerosis	8.62e-07	4.79e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—multiple sclerosis	8.59e-07	4.78e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—multiple sclerosis	8.55e-07	4.75e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK1—multiple sclerosis	8.43e-07	4.69e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—multiple sclerosis	8.24e-07	4.58e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—multiple sclerosis	8.21e-07	4.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—multiple sclerosis	8.06e-07	4.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—multiple sclerosis	8.04e-07	4.47e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—multiple sclerosis	8e-07	4.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—multiple sclerosis	7.99e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK1—multiple sclerosis	7.89e-07	4.39e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—multiple sclerosis	7.65e-07	4.26e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—multiple sclerosis	7.6e-07	4.23e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—multiple sclerosis	7.58e-07	4.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—multiple sclerosis	7.57e-07	4.21e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—multiple sclerosis	7.27e-07	4.04e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—multiple sclerosis	7.06e-07	3.93e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—multiple sclerosis	7.04e-07	3.92e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—multiple sclerosis	6.98e-07	3.88e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK1—multiple sclerosis	6.91e-07	3.84e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—multiple sclerosis	6.73e-07	3.74e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—multiple sclerosis	6.71e-07	3.73e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—multiple sclerosis	6.48e-07	3.6e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—multiple sclerosis	6.25e-07	3.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—multiple sclerosis	6.24e-07	3.47e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK1—multiple sclerosis	6.12e-07	3.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—multiple sclerosis	6.06e-07	3.37e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—multiple sclerosis	5.49e-07	3.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—multiple sclerosis	5.31e-07	2.95e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—multiple sclerosis	4.71e-07	2.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—multiple sclerosis	4.7e-07	2.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—multiple sclerosis	4.3e-07	2.39e-06	CbGpPWpGaD
